U.S., Dec. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07262489) titled 'Neo-adjuvant Immunotherapy Master Trial for Localized Cancers' on Sept. 24.
Brief Summary: Most cancer treatments are developed without knowing whether the drug's targets are actually present in a patient's tumor or whether the patient is likely to benefit from the treatment. In addition, the immune environment surrounding the tumor changes significantly during the course of the disease, and the body's immune response to cancer tends to become less effective in later stages.
Currently, standard blood tests provide only basic information about a patient's immune, inflammatory, and metabolic systems. These tests do not offer a compreh...